The impact of ethnicity on metabolic outcomes during treatment with antipsychotics: Complexities abound

Journal of Clinical Psychiatry

Volumn 70, Issue 11, 2009, Pages 1608-

  Citrome, Leslie ^a,b   Krakowski, Menahem ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

DRUG EFFECT; ETHNIC GROUP; ETHNICITY; HUMAN; LETTER; METABOLIC DISORDER; METABOLIC PARAMETERS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RACE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; ETHNIC GROUPS; HUMANS; METABOLIC SYNDROME X; PHARMACOGENETICS;

EID: 72849141896     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09l05169yel     Document Type: Letter

References (3)

1. Meyer JM, Rosenblatt LC, Kim E, et al. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry. 2009;70(3):318-325. PubMed doi:10.4088/JCP.08m04267
2. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1-3):95-102. PubMed doi:10.1016/j.schres.2009.02.006
3. Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother. 2008;8(7):1079-1091. PubMed doi:10.1586/14737175.8.7.1079 (Pubitemid 351962075)